Pathologic Assessment of NSCLC
Managing patients with non-small cell lung cancer (NSCLC) across the disease continuum is a complex task. Clinicians need to be aware of recent developments in lung cancer screening, as well as the risks and benefits of LDCT screening, so they can appropriately manage their at-risk patients.
For patients diagnosed with cancer, complete pathologic evaluation and staging of the disease is required to ensure appropriate initial and ongoing management. Oncologists need to be aware of the most recent data regarding molecular testing so that optimal therapies can be selected for patients with NSCLC. Recent updates in the management of patients with advanced NSCLC point to specific interventions for advanced disease, including how to select the most appropriate first-line, maintenance, second-line, and third-line systemic therapy. Clinicians should be familiar with the use of appropriate treatment options in the management of patients with ALK-positive or EGFR-positive tumors.
This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Describe the process for determining histology and performing molecular testing for patients with advanced NSCLC
Rudy P. Lackner, MD
UNMC Eppley Cancer Center at
The Nebraska Medical Center
- 0.25 Participation
- 0.20 Nurse
- 0.25 Pharmacist
- 0.25 Physician